Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP01 versus Avastin-EU with carboplatin and paclitaxel in advanced non-squamous NSCLC
2020-005618-16Phase 3Completed
- Sponsor
- CuraTeQ Biologics
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Bevanovis and bevacizumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (2 arms), sponsored by CuraTeQ Biologics. Primary endpoint: Overall response rate. Started Dec 2020; status: completed.
02
Drugs
Bevanovisbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on 2020-005618-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005618-16.